期刊文献+

奥美拉唑肠溶胶囊的人体药物动力学和生物等效性研究 被引量:3

Pharmacokinetics and Bioequivalence of Omeprazole Enteric-coated Capsules in Chinese healthy volunteers
下载PDF
导出
摘要 目的研究奥美拉唑肠溶胶囊在人体内药动学和生物等效性。方法健康志愿者20名,随机双交叉单剂量口服通化神源药业有限公司研制的奥关拉唑肠溶胶囊(试验制剂)和海口康元制药有限公司生产的奥关拉唑肠溶胶囊(参比制剂),剂量分别为40mg.剂间间隔为1周。分别于服药后12h内多点抽取静脉血,用高效液相色谱(HPLC)法测定血浆中奥关拉唑肠溶胶囊的浓度。用DAS(Drug And Statistics,version 2.0)药动学程序计算相对生物利用度并评价两种制剂生物等效性。AUC0-12,AUC(0-inf)和Cmax经方差分析和双单侧t检验,Tmax进行秩和检验。结果单剂量口服奥关拉唑肠溶胶囊试验和参比制剂后,血浆奥关拉唑的Cmax分别为(1146.77±386.58)ng·mL%-1和(1138.93±360、90)ng·mL^-1;Tmax分别为(2.40±0、53)h和(2.28±0.44)h;AUC(0-12)分别为(4853.61±1960.52)ng·h·mL^-1和(4743.06±1740、71)ng·h·mL^-1;AUC(0-inf)分别为(5111.76±2031.72)ng·h·mL^-1和(4942.71±1833.39)ng·h·mL^-1。AUC(0-12)的90%可信区间为94.6-106.3%,AUC(0-inf)的90%可信区间为96.5—107.2%,Cmax的90%可信区间为95.9—104.3%。结论试验制剂与参比制剂的人体相对生物利用度为(101.32±14.90)%,试验制剂与参比制剂具有生物学等效性。 OBJECTIVE To study the Pharmacokinetics and Bioequivalence of Omeprazole Enteric-coated Capsules in Chinese healthy volunteers. METHODS A single oral dose (40mg of tested and reference formulation) were given to 20 healthy volunteers in a randomised crossover study. The concentrations of Trimetazidine in plasma were determined by HPLC. The pharmacokinetics parameters were calculated and the bioavailability and bioequivalence of two formulations were evaluated by DAS program. RESULTS After a single dose,the pharmacokinetics parameters for Trimetazidine were as follows : Cmax were ( 1 146.77 ± 386.58 ) ng · mL^-1 and (1 138.93±360.90)ng · mL^-1; Tmax were (2.40 ±0.53)h and (2.28 ±0.44)h; AUC(0-12)were (4 853.61 ± 1 960.52) ng · h · mL^-1 and (4 743.06 ±1 740.71)ng · h · mL^-1; AUC(0-inf) were (5 111.76 ±2 031.72)ng · h · mL^-1 and (4 942.71 ± 1 833.39)ng · h · mL^-1 for tested and reference formulation respectively. The 90% confidential interval of AUC(0-12) ,AUC(0-inf) and Cmax of tested formulation were 94.6% - 106.3% , 96.5% - 107.2% and 95.9% - 104.3% respectively. CONCLUSION The relative bioavailability was ( 101. 32 ± 14. 90 ) % ; The results of the statistic analysis showed that the two formulations were bioequivalence.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2008年第3期223-226,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 奥关拉唑 药动学 相对生物利用度 生物等效性 高效液相色谱法 omeprazole pharmacokinetics relative bioavailability bioequivalence high performance liquid chromatography
  • 相关文献

参考文献6

二级参考文献18

  • 1de Morais SM, Wilkinson GR, Blaisdell J et al. Identification of a new genetic defect responsible for the polymorphism of (S) -mephenytoin metabolism in Japanese[J]. Mol Pharmacol, 1994,46(4) :594 -8. 被引量:1
  • 2Yamada S, Onda M, Kato S et al . Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations[J]. J Gastroenterol, 2001,36(10) :669 -72. 被引量:1
  • 3Shirai N, Furuta T, Moriyama Yet al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH[J]. Aliment Pharmacol Ther 2001, 15(12) :1929 - 37. 被引量:1
  • 4Sakai T, Aoyama N, Kita T et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects[J]. Pharm Res, 2001,18(6) :721 -7. 被引量:1
  • 5Andersson T, Cederberg C, Edvardsson G et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole[J]. Clin Pharmacol Ther, 1990,47(1) :79 -85. 被引量:1
  • 6Andersson T, Andren K, Cederberg C et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects[J]. Br J Clin Pharmacol, 1990,29(5) :557 -63. 被引量:1
  • 7Furuta T, Ohashl K, Kosuge K et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans[J]. Clin Pharmacol Ther, 1999, 65(5) : 552 -61. 被引量:1
  • 8Shimatani T, lnoue M, Kuroiwa T et al. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist[J]. Aliment Pharmacol Ther, 2003,18 ( 11-12) :1149 -57. 被引量:1
  • 9Abelo A, Eriksson UG, Karlsson MO et al. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog[J]. J Pharmacol Exp Ther,2000,295(2) :662 -9. 被引量:1
  • 10Manes G, Pieramico O, Perri F, Vaira D, Giardullo N, Romano M, et al. Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy[J]. Dig Dis Sci, 2005; 50: 443-8 被引量:1

共引文献40

同被引文献1991

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部